{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:57:35Z","timestamp":1785938255576,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["2008P000320"],"award-info":[{"award-number":["2008P000320"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.urolonc.2025.08.030","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:39:43Z","timestamp":1760139583000},"page":"709.e9-709.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["PSA density as a dynamic prognostic marker of biopsy grade progression during active surveillance"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1480-8716","authenticated-orcid":false,"given":"Andrew","family":"Gusev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rumpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitar","family":"Zlatev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey K.","family":"Twum-Ampofo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F.","family":"Wszolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Blute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyan","family":"Salari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-9091","authenticated-orcid":false,"given":"Adam S.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.08.030_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort","author":"Tosoian","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.08.030_bib0002","article-title":"Long-term outcomes of active surveillance for prostate cancer: the memorial Sloan Kettering cancer center experience","author":"Carlsson","year":"2019","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.030_bib0003","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2012.11.005","article-title":"Active surveillance for low-risk prostate cancer worldwide: the PRIAS study","volume":"63","author":"Bul","year":"2013","journal-title":"Eur Urol"},{"issue":"3 Pt 1","key":"10.1016\/j.urolonc.2025.08.030_bib0004","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.juro.2016.09.070","article-title":"Targeted biopsy to detect gleason score upgrading during active surveillance for men with low versus intermediate risk prostate cancer","volume":"197","author":"Nassiri","year":"2017","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.030_bib0005","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/bju.13836","article-title":"Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer","volume":"120","author":"Alberts","year":"2017","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.urolonc.2025.08.030_bib0006","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2214\/AJR.19.21559","article-title":"MRI-based prostate-specific antigen density predicts gleason score upgrade in an active surveillance cohort","volume":"214","author":"WA","year":"2020","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.030_bib0007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.urpr.2018.05.007","article-title":"Role of multiparametric Magnetic resonance imaging prostate specific antigen density and PI-RADS\u2122 score in predicting up staging in men on active surveillance","volume":"6","author":"Van Kuiken","year":"2019","journal-title":"Urol Pract"},{"key":"10.1016\/j.urolonc.2025.08.030_bib0008","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000001088","article-title":"Magnetic resonance imaging for the detection of high-grade cancer in the Canary prostate active surveillance study","author":"Liss","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.08.030_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.3187","article-title":"Tailoring intensity of active surveillance for low-risk prostate cancer based on individualized prediction of risk stability","author":"Cooperberg","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.030_bib0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.eururo.2018.01.017","article-title":"Refined analysis of prostate-specific antigen kinetics to predict prostate cancer active surveillance outcomes","volume":"74","author":"Cooperberg","year":"2018","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.030_bib0011","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.eururo.2013.08.060","article-title":"Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies","volume":"66","author":"Cary","year":"2014","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.08.030_bib0012","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.juro.2016.03.179","article-title":"Serial anatomical prostate ultrasound during prostate cancer active surveillance","volume":"196","author":"Eltemamy","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.08.030_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2020.03.035","article-title":"Five-year outcomes of Magnetic resonance imaging\u2013based active surveillance for prostate cancer: a large cohort study","author":"Stavrinides","year":"2020","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.030_bib0014","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.eururo.2016.06.011","article-title":"Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations-A report of a European School of Oncology Task Force","volume":"71","author":"Moore","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.08.030_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/bju.15065","article-title":"Prostate cancer upgrading with serial prostate MRI scans and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?","author":"Osses","year":"2020","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.030_bib0016","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2019.12.009","article-title":"Role of changes in magnetic resonance imaging or clinical stage in evaluation of disease progression for men with prostate cancer on active surveillance","volume":"77","author":"Chesnut","year":"2020","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.030_bib0017","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.juro.2018.05.016","article-title":"Prostate specific antigen density as a predictor of clinically significant Prostate cancer when the Prostate specific antigen is in the diagnostic gray zone: defining the optimum cutoff point stratified by race and body mass index","volume":"200","author":"Aminsharifi","year":"2018","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.08.030_bib0018","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.29874","article-title":"Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies","volume":"122","author":"Filson","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2025.08.030_bib0019","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.juro.2017.03.130","article-title":"The value of PSA density in combination with PI-RADS for the accuracy of prostate cancer prediction","volume":"198","author":"Distler","year":"2017","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.08.030_bib0020","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/bju.13619","article-title":"The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting","volume":"119","author":"Hansen","year":"2017","journal-title":"BJU International"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.030_bib0021","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/bju.13465","article-title":"Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients","volume":"119","author":"Washino","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.08.030_bib0022","doi-asserted-by":"crossref","DOI":"10.1111\/bju.15037","article-title":"Association between PSA density and prostate cancer in men without significant MRI lesions","author":"Mortezavi","year":"2020","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.030_bib0023","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.juro.2006.09.039","article-title":"Prostate specific antigen density correlates with features of prostate cancer aggressiveness","volume":"177","author":"Kundu","year":"2007","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.08.030_bib0024","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.juro.2012.07.106","article-title":"Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosis","volume":"188","author":"Busch","year":"2012","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.030_bib0025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.juro.2009.08.139","article-title":"Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience","volume":"183","author":"Magheli","year":"2010","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.08.030_bib0026","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.urology.2007.01.087","article-title":"Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure","volume":"69","author":"Radwan","year":"2007","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.030_bib0027","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5489\/cuaj.329","article-title":"PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer","volume":"6","author":"Sfoungaristos","year":"2012","journal-title":"Can Urol Assoc J"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.030_bib0028","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.urology.2014.02.038","article-title":"Prostate-specific antigen density toward a better cutoff to identify better candidates for active surveillance","volume":"84","author":"Ha","year":"2014","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.urolonc.2025.08.030_bib0029","doi-asserted-by":"crossref","first-page":"624","DOI":"10.4111\/kju.2015.56.9.624","article-title":"Pathological upgrading in prostate cancer patients eligible for active surveillance: does prostate-specific antigen density matter?","volume":"56","author":"Jin","year":"2015","journal-title":"Korean J Urol"},{"key":"10.1016\/j.urolonc.2025.08.030_bib0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.urology.2017.07.071","article-title":"Prostate-specific antigen density is a good predictor of upstaging and upgrading, according to the new grading system: the keys we are seeking may Be already in our pocket","volume":"111","author":"Brassetti","year":"2018","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.030_bib0031","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/pcan.2010.36","article-title":"Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance","volume":"14","author":"Kotb","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.030_bib0032","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.eururo.2011.06.027","article-title":"Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program","volume":"61","author":"Bul","year":"2012","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.030_bib0033","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.juro.2010.09.115","article-title":"Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance","volume":"185","author":"San Francisco","year":"2011","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.08.030_bib0034","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.juro.2010.01.001","article-title":"Risk stratification of men choosing surveillance for low risk prostate cancer","volume":"183","author":"Tseng","year":"2010","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.030_bib0035","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.eururo.2006.12.017","article-title":"Methods of calculating prostate-specific antigen velocity","volume":"52","author":"Connolly","year":"2007","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.030_bib0036","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1198\/000313005X70371","article-title":"Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator","volume":"59","author":"Snapinn","year":"2005","journal-title":"Am Statist"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.030_bib0037","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.juro.2010.09.095","article-title":"Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer","volume":"185","author":"Adamy","year":"2011","journal-title":"J Urol"},{"issue":"17","key":"10.1016\/j.urolonc.2025.08.030_bib0038","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2009.25.7311","article-title":"Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program","volume":"28","author":"Ross","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.08.030_bib0039","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1464-410X.2012.11295.x","article-title":"Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients","volume":"111","author":"Iremashvili","year":"2013","journal-title":"BJU Int"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T11:56:19Z","timestamp":1766145379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925003527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1078143925003527"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.08.030","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSA density as a dynamic prognostic marker of biopsy grade progression during active surveillance","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}